gRNA 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, gRNA 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

gRNA Market Summary

The global gRNA market size was estimated at USD 579.5 million in 2024 and is projected to reach USD 2.66 billion by 2033, growing at a CAGR of 18.64% from 2025 to 2033. gRNA is in high demand because it is essential for CRISPR-based genetic editing.

Its ability to accurately guide the CRISPR system to specific DNA sequences enables precise gene modifications, driving breakthroughs in medicine, agriculture, and biotechnology.

Expansion of CRISPR Gene Editing Applications

The global demand for gRNA is rising sharply due to the rapid expansion of CRISPR applications across research and industry. As the critical element that directs CRISPR to specific DNA or RNA targets, every CRISPR workflow depends on precise and reliable gRNA. Increasing use of CRISPR in functional genomics, knockout/knock-in studies, engineered cell models, and high-throughput screening has driven strong growth in customized gRNA consumption. With CRISPR advancing from research to clinical and therapeutic applications, especially in gene therapy and precision medicine, more biopharma and academic labs are adopting the technology, further escalating the need for specialized gRNA. For instance, in October 2021, in Germany, Merck licensed its patented CRISPR-Cas9 technology to Cellecta, enabling advanced knock-in applications.

The growing diversification of CRISPR systems is further boosting demand for tailored gRNA products. As gene-editing advances from traditional Cas9 to next-generation tools like Cas12 and Cas13 for RNA targeting, for compact delivery, and platforms such as base and prime editing, researchers require highly optimized gRNAs with greater efficiency and minimal off-target effects.

Global gRNA Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global gRNA market report based on product & services, gRNA type, application, end-use, and region:

• Product & Service Outlook (Revenue in USD Million, 2021 - 2033)
• Products
  • gRNA Final Products
  • gRNA Synthesis Products
  • gRNA Synthesis Kits
  • Plasmids
  • Others
• Custom gRNA Synthesis Services
• gRNA Type Outlook (Revenue, USD Million, 2021 - 2033)
• Research-Use
• GMP-grade
• Application Outlook (Revenue, USD Million; 2021 - 2033)
• Genome Engineering
• Disease Model Studies
• Functional Genomics
• Epigenetics
• Others
• End-use Outlook (Revenue, USD Million; 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic Research Institutes
• CMOs & CROs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service
  • 1.2.2. gRNA Type
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. gRNA Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. gRNA Market Variables and Trends

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Expansion of CRISPR gene editing applications
  • 3.4.2. Growing R&D in proteomics and genomics
• 3.5. Market Restraint Analysis
  • 3.5.1. Regulatory Challenges
  • 3.5.2. Off-Target Effects and Safety Concerns
• 3.6. Business Environment Analysis
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTLE Analysis

Chapter 4. Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. gRNA market: Product & Service Movement Analysis
• 4.3. Products
  • 4.3.1. Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.2. gRNA Final Products
    • 4.3.2.1. gRNA Final Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3.3. gRNA Synthesis Products
    • 4.3.3.1. gRNA Synthesis Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.2. gRNA Synthesis Kits
      • 4.3.3.2.1. gRNA Synthesis Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.3. Plasmids
      • 4.3.3.3.1. Plasmids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3.4. Others
      • 4.3.3.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Custom gRNA Synthesis Services
  • 4.4.1. Custom gRNA Synthesis Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. gRNA Type Estimates & Trend Analysis

• 5.1. gRNA Type Segment Dashboard
• 5.2. gRNA market: gRNA Type Movement Analysis
• 5.3. Research-Use
  • 5.3.1. Research-Use Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. GMP-grade
  • 5.4.1. GMP-grade Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. gRNA market: Application Movement Analysis
• 6.3. Genome Engineering
  • 6.3.1. Genome Engineering Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Disease Model Studies
  • 6.4.1. Disease Model Studies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Functional Genomics
  • 6.5.1. Functional Genomics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Epigenetics
  • 6.6.1. Epigenetics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. gRNA market: End-Use Movement Analysis
• 7.3. Pharmaceutical & Biotechnology Companies
  • 7.3.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Academic Research Institutes
  • 7.4.1. Academic Research Institutes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. CMOs & CROs
  • 7.5.1. CMOs & CROs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 8.4. North America
  • 8.4.1. North America gRNA Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. U.S. gRNA Market, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. Canada gRNA Market, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. Mexico gRNA Market, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. UK gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Germany gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.4. Spain
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. Spain gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.5. France
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Target Disease Prevalence
    • 8.5.5.5. France gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.6. Italy
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Target Disease Prevalence
    • 8.5.6.5. Italy gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Target Disease Prevalence
    • 8.5.7.5. Denmark gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Target Disease Prevalence
    • 8.5.8.5. Sweden gRNA Market, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Target Disease Prevalence
    • 8.5.9.5. Norway gRNA Market, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia-Pacific gRNA Market, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. Japan gRNA Market, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. China gRNA Market, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. India gRNA Market, 2021 - 2033 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. South Korea gRNA Market, 2021 - 2033 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Target Disease Prevalence
    • 8.6.6.5. Thailand gRNA Market, 2021 - 2033 (USD Million)
  • 8.6.7. Australia
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Target Disease Prevalence
    • 8.6.7.5. Australia gRNA Market, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America gRNA Market, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Target Disease Prevalence
    • 8.7.2.5. Brazil gRNA Market, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Target Disease Prevalence
    • 8.7.3.5. Argentina gRNA Market, 2021 - 2033 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA gRNA Market, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Target Disease Prevalence
    • 8.8.2.5. South Africa gRNA Market, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Target Disease Prevalence
    • 8.8.3.5. Saudi Arabia gRNA Market, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Target Disease Prevalence
    • 8.8.4.5. UAE gRNA Market, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Target Disease Prevalence
    • 8.8.5.5. Kuwait gRNA Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Market Position Analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Thermo Fisher Scientific, Inc
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Agilent Technologies, Inc.
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. System Biosciences, LLC.
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Jena Bioscience GmbH
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Merck KGaA
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Azenta Life Sciences (Genewiz)
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Benchmarking
    • 9.4.6.3. Strategic Initiatives
  • 9.4.7. Takara Bio Inc.
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Synbio Technologies
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Revvity Inc (Horizon Discovery Ltd.)
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Synthego
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives